Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study

Lane, Wendy; Faurby, Mads; Husemoen, Lise Lotte Nystrup; Markovich, Dmitriy L.; Rathor, Naveen; Block, Christophe De

doi:10.1007/s13300-021-01165-0

Cited by 3 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as all the above‐mentioned RCTs were treat‐to‐target studies, no differences in HbA1c were to be expected. In real‐world conditions, small improvements in HbA1c or in TIR have been documented with the use of Fiasp 68‐70 . It is important to note that, in most RCTs, the evaluation of PPG levels was based on liquid meal tests, which differ from solid mixed meals that patients consume in real‐life settings.…”

Section: Discussionmentioning

confidence: 99%

“…In real-world conditions, small improvements in HbA1c or in TIR have been documented with the use of Fiasp. [68][69][70] It is important to note that, in most RCTs, the evaluation of PPG levels was based on liquid meal tests, which differ from solid mixed meals that patients consume in real-life settings. However, CGM also showed similar beneficial effects in real-life conditions.…”

Section: Discussionmentioning

confidence: 99%

“…Billion et al, studying 438 adults with T1D, showed a 5% increase in time in range (TIR: 70-180 mg/dl), corresponding to 75 min/day, in combination with less time spent below and above range, 12 months after switching from any mealtime insulin to Fiasp 69. Lane et al observed a clinically relevant reduction in HbA1c 6 months after initiating Fiasp treatment for individuals with T2D, but not T1D, although patients with baseline HbA1c of more than 8.5% had significant HbA1c reductions, regardless of diabetes type 70. …”

mentioning

confidence: 99%

See 2 more Smart Citations

Rapid‐acting insulin analogues: Theory and best clinical practice in type 1 and type 2 diabetes

Block

Cauwenberghe

Bochanen

et al. 2022

Diabetes Obesity Metabolism

Self Cite

View full text Add to dashboard Cite

Since the discovery of insulin 100 years ago, insulin preparations have improved significantly. Starting from purified animal insulins, evolving to human insulins produced by genetically modified organisms, and ultimately to insulin analogues, all in an attempt to mimic physiological insulin action profiles seen in individuals without diabetes. Achieving strict glucose control without hypoglycaemia and preventing chronic complications of diabetes while preserving quality of life remains a challenging goal, but the advent of newer ultra-rapid-acting insulin analogues may enable intensive insulin therapy without being too disruptive to daily life. Ultra-rapid-acting insulin analogues can be administered shortly before meals and give better coverage of mealtime-induced glucose excursions than conventional insulin preparations. They also increase convenience with timing of bolus dosing. In this review, we focus on the progress that has been made in rapid-acting insulins. We summarize pharmacokinetic and pharmacodynamic data, clinical trial data supporting the use of these new formulations as part of a basal-bolus regimen and continuous subcutaneous insulin infusion, and provide a clinical perspective to help guide healthcare professionals when and for whom to use ultra-fast-acting insulins.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation